<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shamekh MM</submitter><funding>Egyptian Cultural and Educational Bureau</funding><funding>Karolinska Institutet</funding><funding>IngaBritt och Arne Lundbergs Forskningsstiftelse (Ingabritt and Arne Lundberg Research Foundation)</funding><funding>IngaBritt och Arne Lundbergs Forskningsstiftelse</funding><pagination>114</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12847883</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(1)</volume><pubmed_abstract>Glucocorticoids (GCs) are known for their anti-inflammatory potential, which includes the macrophage polarization into an anti-inflammatory and tissue remodeling state. GCs are routinely co-administered to cancer patients to alleviate the side effects of chemotherapy. However, it is not well known if GCs can modulate tumor-associated macrophages (TAMs) to promote tumor progression. Here, we show that dexamethasone (DEX) induces dose-dependent differentiation of THP-1 monocyte-derived anti-tumorigenic (M1) macrophages into pro-tumorigenic (M2-like) macrophages, even in the presence of M1 cues, and that DEX can repolarize fully differentiated M1 macrophages into an M2-like state. These macrophages have a cytokine profile similar to the pro-tumorigenic (M2) macrophages and can stimulate the p</pubmed_abstract><journal>Cell death &amp; disease</journal><pubmed_title>Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness.</pubmed_title><pmcid>PMC12847883</pmcid><funding_grant_id>LU2022-0025</funding_grant_id><pubmed_authors>Nalvarte I</pubmed_authors><pubmed_authors>Shamekh MM</pubmed_authors><pubmed_authors>Lindqvist B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness.</name><description>Glucocorticoids (GCs) are known for their anti-inflammatory potential, which includes the macrophage polarization into an anti-inflammatory and tissue remodeling state. GCs are routinely co-administered to cancer patients to alleviate the side effects of chemotherapy. However, it is not well known if GCs can modulate tumor-associated macrophages (TAMs) to promote tumor progression. Here, we show that dexamethasone (DEX) induces dose-dependent differentiation of THP-1 monocyte-derived anti-tumorigenic (M1) macrophages into pro-tumorigenic (M2-like) macrophages, even in the presence of M1 cues, and that DEX can repolarize fully differentiated M1 macrophages into an M2-like state. These macrophages have a cytokine profile similar to the pro-tumorigenic (M2) macrophages and can stimulate the p</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-09T06:56:36.121Z</modification><creation>2026-06-09T03:11:50.996Z</creation></dates><accession>S-EPMC12847883</accession><cross_references><pubmed>41413093</pubmed><doi>10.1038/s41419-025-08363-9</doi></cross_references></HashMap>